Inada Ken, Ishigooka Jun
Department of Psychiatry, School of Medicine, Tokyo Women's Medical University.
Nihon Rinsho. 2013 Apr;71(4):678-83.
Clozapine is a drug used in the management of treatment-resistant schizophrenia. Numerous clinical trials, including randomized double-blind clinical trials and large cohort studies, have revealed that clozapine is more effective than any other antipsychotic drugs. However, the same studies have also shown that this drug has several adverse effects such as an agranulocytosis. Therefore, in Japan, clozapine is approved for administration to only patients with treatment-resistant schizophrenia in whom treatment with other antipsychotic drugs was ineffective. Clozapine is prescribed only at approved institutes that are under the registration called Clozaril Patient Monitoring Service (CPMS), and white blood cell counts and prescription dosage of clozapine are strictly monitored under this service.
氯氮平是一种用于治疗难治性精神分裂症的药物。众多临床试验,包括随机双盲临床试验和大型队列研究,均表明氯氮平比其他任何抗精神病药物都更有效。然而,同样的研究也表明,这种药物有多种不良反应,如粒细胞缺乏症。因此,在日本,氯氮平仅被批准用于其他抗精神病药物治疗无效的难治性精神分裂症患者。氯氮平仅在名为氯氮平患者监测服务(CPMS)注册的获批机构开具处方,并且在此服务下会严格监测白细胞计数和氯氮平的处方剂量。